346 related articles for article (PubMed ID: 32495677)
1. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation.
Yu HT; Yang PS; Jang E; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
J Am Heart Assoc; 2020 Jun; 9(12):e014177. PubMed ID: 32495677
[TBL] [Abstract][Full Text] [Related]
2. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
[TBL] [Abstract][Full Text] [Related]
3. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
4. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
[TBL] [Abstract][Full Text] [Related]
5. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
[TBL] [Abstract][Full Text] [Related]
6. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.
Chan YH; Chao TF; Chen SW; Lee HF; Yeh YH; Huang YC; Chang SH; Kuo CT; Lip GYH; Chen SA
Heart Rhythm; 2020 Dec; 17(12):2102-2110. PubMed ID: 32702416
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
8. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
[TBL] [Abstract][Full Text] [Related]
9. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
Lee SR; Lee YS; Park JS; Cha MJ; Kim TH; Park J; Park JK; Lee JM; Kang KW; Shim J; Uhm JS; Kim J; Kim C; Kim JB; Park HW; Joung B; Choi EK
Yonsei Med J; 2019 Mar; 60(3):277-284. PubMed ID: 30799590
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis.
Caso V; de Groot JR; Sanmartin Fernandez M; Segura T; Blomström-Lundqvist C; Hargroves D; Antoniou S; Williams H; Worsley A; Harris J; Caleyachetty A; Vardar B; Field P; Ruff CT
Heart; 2023 Jan; 109(3):178-185. PubMed ID: 36316100
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort.
Bonde AN; Martinussen T; Lee CJ; Lip GYH; Staerk L; Bang CN; Bhattacharya J; Gislason G; Torp-Pedersen C; Olesen JB; Hlatky MA
Circ Cardiovasc Qual Outcomes; 2020 Apr; 13(4):e006058. PubMed ID: 32283966
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
[TBL] [Abstract][Full Text] [Related]
14. Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage.
Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
Stroke; 2020 Feb; 51(2):416-423. PubMed ID: 31813363
[TBL] [Abstract][Full Text] [Related]
15. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.
Song HY; Son KB; Shin JY; Bae S
Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377
[TBL] [Abstract][Full Text] [Related]
16. Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge.
Kartas A; Samaras A; Vasdeki D; Dividis G; Fotos G; Paschou E; Forozidou E; Tsoukra P; Kotsi E; Goulas I; Efthimiadis G; Karvounis H; Tzikas A; Giannakoulas G
J Cardiovasc Pharmacol Ther; 2019 May; 24(3):225-232. PubMed ID: 30599759
[TBL] [Abstract][Full Text] [Related]
17. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
[TBL] [Abstract][Full Text] [Related]
18. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants.
Camm AJ; Cools F; Virdone S; Bassand JP; Fitzmaurice DA; Arthur Fox KA; Goldhaber SZ; Goto S; Haas S; Mantovani LG; Kayani G; Grierson Turpie AG; Antoon Verheugt FW; Kakkar AK;
J Am Coll Cardiol; 2020 Sep; 76(12):1425-1436. PubMed ID: 32943160
[TBL] [Abstract][Full Text] [Related]
19. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
